Therapeutic bronchoscopy for malignant central airway obstructions caused by non-bronchogenic cancers: Results from the EpiGETIF registry.

interventional pulmonology malignant central airway obstruction registry thoracic metastasis

Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
18 Apr 2024
Historique:
received: 10 01 2024
accepted: 02 04 2024
medline: 18 4 2024
pubmed: 18 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non-bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB). In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022. From a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01-2.18]), prior oncologic treatment received (HR 1.82 [1.28-2.56], p < 0.001) and assessment of success at the end of the procedure (HR 0.66 [0.44-0.99], p < 0.001). Complications rate was 8.8%, mostly mild, with no procedure-related mortality. TB for MCAO caused by a NBC metastasis provides rapid improvement of symptoms and prolonged survival. Patients should be promptly referred by medical oncologists for bronchoscopic management based on the prognostic factors identified.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non-bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB).
METHODS METHODS
In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022.
RESULTS RESULTS
From a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01-2.18]), prior oncologic treatment received (HR 1.82 [1.28-2.56], p < 0.001) and assessment of success at the end of the procedure (HR 0.66 [0.44-0.99], p < 0.001). Complications rate was 8.8%, mostly mild, with no procedure-related mortality.
CONCLUSION CONCLUSIONS
TB for MCAO caused by a NBC metastasis provides rapid improvement of symptoms and prolonged survival. Patients should be promptly referred by medical oncologists for bronchoscopic management based on the prognostic factors identified.

Identifiants

pubmed: 38634359
doi: 10.1111/resp.14723
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : AstraZeneca France
Organisme : PulmonX
Organisme : Novatech

Informations de copyright

© 2024 Asian Pacific Society of Respirology.

Références

Murgu SD, Egressy K, Laxmanan B, Doblare G, Ortiz‐Comino R, Hogarth DK. Central airway obstruction: benign strictures, tracheobronchomalacia, and malignancy‐related obstruction. Chest. 2016;150:426–441.
Guibert N, Mhanna L, Droneau S, Plat G, Didier A, Mazieres J, et al. Techniques of endoscopic airway tumor treatment. J Thorac Dis. 2016;8:3343–3360.
Guibert N, Mazieres J, Lepage B, Plat G, Didier A, Hermant C. Prognostic factors associated with interventional bronchoscopy in lung cancer. Ann Thorac Surg. 2014;97:253–259.
Ost DE, Ernst A, Grosu HB, Lei X, Diaz‐Mendoza J, Slade M, et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest. 2015;147(5):1282–1298.
Freitas C, Serino M, Cardoso C, Saleiro S, Vaz AP, Novais‐Bastos H, et al. Predictors of survival and technical success of bronchoscopic interventions in malignant airway obstruction. J Thorac Dis. 2021;13(12):6760–6768.
Puchalski J. Pulmonary manifestations of solid non‐pulmonary malignancies. Clin Chest Med. 2017 Jun;38(2):177–186. https://doi.org/10.1016/j.ccm.2016.12.002
Chaussende A, Hermant C, Tazi‐Mezalek R, Favrolt N, Hureaux J, Fournier C, et al. Endobronchial metastases from melanoma: a survival analysis. Clin Respir J. 2017 Nov;11(6):1006–1011. https://doi.org/10.1111/crj.12456
Fournel C, Bertoletti L, Nguyen B, Vergnon JM. Endobronchial metastases from colorectal cancers: natural history and role of interventional bronchoscopy. Respiration. 2009;77(1):63–69. https://doi.org/10.1159/000158487
Doğan D, Turan D, Özgül MA, Çetinkaya E. The role of interventional pulmonology in endobronchial metastasis of renal cell carcinoma. Tuberk Toraks. 2019 Sep;67(3):211–218. English. https://doi.org/10.5578/tt.68407
Sørensen JB. Endobronchial metastases from extrapulmonary solid tumors. Acta Oncol. 2004;43(1):73–79. https://doi.org/10.1080/02841860310018053
Guibert N, Roy P, Amari L, Legodec J, Escarguel B, Fournier C, et al. Therapeutic bronchoscopy for malignant central airway obstruction: Introduction to the EpiGETIF registry. Respirology. 2024.
Marchioni A, Lasagni A, Busca A, Cavazza A, Agostini L, Migaldi M, et al. Endobronchial metastasis: an epidemiologic and clinicopathologic study of 174 consecutive cases. Lung Cancer. 2014 Jun;84(3):222–228. https://doi.org/10.1016/j.lungcan.2014.03.005
Edme J, Fournier C, Obando CZ, Cellerin L, Wallyn F, Lachkar S, et al. Prognostic factors after airway stenting for malignant tracheo‐ or broncho‐oesophageal fistulas. Eur Respir J. 2023;62:PA463.

Auteurs

Clément Daigmorte (C)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.

Daniela Usturoi (D)

Thoracic Surgery Department, Foch-Suresnes University Hospital, Paris, France.

Clément Fournier (C)

Pulmonology Department, Heart and Lung Institute, CHU Lille, Lille, France.

Frederic Wallyn (F)

Pulmonology Department, Heart and Lung Institute, CHU Lille, Lille, France.

Christine Lorut (C)

Pulmonology Department, Cochin University Hospital, Paris, France.

Valentin Héluain (V)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.

Julien Mazières (J)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.

Julien Legodec (J)

Pulmonology Department, Saint Joseph Hospital, Marseille, France.

Bruno Escarguel (B)

Pulmonology Department, Saint Joseph Hospital, Marseille, France.

Thomas Egenod (T)

Pulmonology Department, Limoges University Hospital, Limoges, France.

Laurent Cellerin (L)

Pulmonology Department, Nantes University Hospital, Nantes, France.

Nicolas Favrolt (N)

Pulmonology Department, Dijon-Bourgogne University Hospital, Dijon, France.

Samy Lachkar (S)

Pulmonology Department, Rouen University Hospital, Rouen, France.

Adrian Crutu (A)

Pulmonology Department, Marie Lannelongue Hospital, France.

Amandine Briault (A)

Pulmonology Department, Grenoble Alpes University Hospital, Grenoble, France.

Christophe Gut-Gobert (C)

Pulmonology Department, Brest University Hospital, Brest, France.

Valerian Bourinet (V)

Pulmonology Department, Saint Pierre University Hospital, Saint Pierre, France.

Juliette Camuset (J)

Pulmonology Department, Tenon University Hospital, Paris, France.

Perrot Loïc (P)

Pulmonology Department, Institut Mutualiste Montsouris, Paris, France.

Pascal Schlossmacher (P)

Department of Pneumology, University Hospital of La Reunion, Saint Denis, France.

Michele Porzio (M)

Pulmonology Department, Strasbourg University Hospital, Strasbourg, France.

Antoine Luchez (A)

Pulmonology Department, Hôpital privé de la Loire, Saint Etienne, France.

Jean-Michel Vergnon (JM)

Pulmonology Department, Saint Etienne University Hospital, Saint Etienne, France.

Marie-Christelle Pajiep Chapda (MC)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.
MeDatas, CIC (Centre d'Investigation Clinique), CHU Toulouse, Toulouse, France.

Pascalin Roy (P)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.
Pulmonology Department, Institut Universitaire de Cardiologie et de Pneumologie de, Québec, Québec, Canada.

Hervé Dutau (H)

Pulmonology Department, Marseille Nord University Hospital, Marseille, France.

Nicolas Guibert (N)

Pulmonology Department, Toulouse University Hospital, Toulouse, France.

Classifications MeSH